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Background. Cardiac troponin T (cTnT) is related to left
ventricular (LV) mass in patients with end-stage renal disease
(ESRD). Furthermore, cTnT reflects the severity of systolic
The risk of cardiovascular complications in patientsdysfunction in patients with heart diseases. We tested the diag-
with end-stage renal disease (ESRD) is by far greaternostic value of cTnT for left ventricular hypertrophy (LVH)
and LV systolic dysfunction in a large group of clinically stable than in the general population [1]. Heart disease, in par-
hemodialysis patients without heart failure. ticular, appears pervasive because the prevalence rates of
Results. CTnT was significantly (P  0.001) higher in pa- coronary heart disease and left ventricular hypertrophytients with LVH than in those with normal LV mass. In a
(LVH) are approximately 40% and 70% and becausemultiple logistic regression model, adjusting for potential con-
about 1/3 of patients on chronic dialysis are affected byfounders (including cardiac ischemia), systolic pressure and
cTnT (both P  0.003) were the strongest correlates of LVH. heart failure. Alterations in LV mass and function are
Similarly, cTnT was significantly higher (P 0.005) in patients currently evaluated by means of electrocardiogram (ECG)
with systolic dysfunction than in those with normal LV function or by echocardiography, but it is felt that echocardiogra-
and in a multiple logistic regression model cTnT ranked as the
phy is applied less than required by nephrologists andsecond independent correlate of this alteration after male sex.
dialysis physicians. Although attention has focused onSerum cTnT had a high positive prediction value for the diagno-
sis of LVH (87%) but its negative prediction value was rela- new markers of cardiac risk like the cardiac hormone
tively low (44%). The positive predictive value of cTnT for LV brain natriuretic peptide (BNP) [2, 3] and on myocardial
dysfunction was low (25%) while its negative predictive value proteins released during myocardial ischemia and necro-
was high (93%). A combined analysis including systolic pres-
sis like troponin T (cTnT) and troponin I (cTnI) [4–7],sure (for the diagnosis of LVH) and sex (for the diagnosis of
the measurement of these substances is still scarcely ap-LV systolic dysfunction) augmented the diagnostic estimates
to an important extent (95% positive prediction value for LVH plied in clinical practice in dialysis patients.
and 98% negative prediction value for LV systolic dysfunction). Troponin T is a strong predictor of adverse outcomes
Conclusions. CTnT has a fairly good diagnostic potential in myocardial infarction [8] and unstable angina [9]. In
for the identification of LVH and for the exclusion of LV
patients with ESRD CTnT is frequently elevated, andsystolic dysfunction in patients with ESRD without heart fail-
for this reason it was considered of questionable valueure. This marker may be useful for the screening of alterations
for the diagnosis of cardiac ischemia in these patients
[10–11]. On the other hand, there is growing evidence
1 Please refer to the Acknowledgments section. that this cardiac protein is a strong predictor of mortality
and cardiovascular outcomes in clinically stable patientsKey words: left ventricular hypertrophy, cardiovascular risk, hemodial-
ysis, uremia, hypertension, diagnosis, end-stage renal disease. [4–7]. We (abstract; Mallamaci F et al, Nephrol Dial
Transplant 16:A148, 2001) and other investigators [12]Received for publication January 3, 2002
have recently observed that cTnT is not only associatedand in revised form May 13, 2002
Accepted for publication June 24, 2002 to all-cause and cardiovascular mortality, but also is
strongly related to LV mass. On these grounds we sug- 2002 by the International Society of Nephrology
1884
Mallamaci et al: Troponin T, LVH and LV systolic dysfunction 1885
gested that it be shown for risk stratification in patients verting enzyme (ACE) inhibitors, angiotensin II subtype 1
(AT1) antagonists, calcium channel blockers, alpha andwith chronic renal failure. Furthermore, observations in
beta blockers, and 24 on double or triple therapy withthe general population indicate that myocardial function
various combinations of these drugs.is an important determinant of circulating troponins be-
cause specific isoforms of cTnT are overexpressed in the
Laboratory measurementsfailing human heart [13], and in patients with heart fail-
Blood sampling was performed between 8:00 am andure cTnT and cTnI reflect disease severity [14–17].
10.00 am, with the patients in steady state conditions,Beyond risk stratification, the associations between
during a non-dialysis day. No patient had inter-currentcTnT and LV mass and function suggest that this protein
acute coronary syndromes at the time of the study. Sam-may be useful to identify patients with LVH and systolic
ples for the measurement of serum cardiac cTnT weredysfunction. On the basis of data collected in patients
taken after 20 to 30 minutes of quiet resting in semire-with essential hypertension [18], we estimated that cTnI
cumbent position. cTnT was measured by a commerciallyhas a 63% sensitivity and 100% specificity for the diagno-
available electrochemiluminescence immunoassay (Elec-sis of LVH. Because the issue of properly identifying
sys 1010/2010 Troponin T Stat, 3rd generation; Roche Di-alterations in cardiac mass and function in uremic pa-
agnostics, Mannheim, Germany). This immunoassay em-tients on chronic dialysis treatment is of paramount im-
ploys two monoclonal antibodies specifically directedportance [19], we investigated the diagnostic potential
against human cardiac cTnT and it is calibrated usingof cTnT for LVH and LV dysfunction in a large group
human recombinant cardiac cTnT. In studies performedof dialysis patients.
with this assay in healthy subjects (N 1951) the 99% CI
was 10 ng/L, and this value also represented the detection
METHODS limit of the assay. The recommended diagnostic thresh-
old for cardiac ischemia is 100 ng/L. The intra-assay preci-Protocol
sion is 1.1 to 1.4%. All samples were stored at60C andThe protocol was in conformity to the ethical guide-
processed in a single assay, at the end of the study.lines of our institutions and informed consent was ob-
Serum lipids, albumin, calcium, phosphate and hemo-tained from each participant. All studies were performed
globin measurements were made using standard methodsduring a non-dialysis day, between 8 am and 1 pm.
in the routine clinical laboratory. C-reactive protein (CRP)
was measured by a commercially available kit (Behring,Study cohort
Scoppito, L’Aquila, Italy). Plasma homocysteine was
One hundred and ninety-nine patients with ESRD measured using a previously described high-pressure liq-
(111 males and 88 females) who had been on regular uid chromatography (HPLC) method [20].
dialysis treatment (RDT) for at least six months (median
duration of RDT 44 months, inter-quartile range 21 to Echocardiography
110 months) without a history of congestive heart failure Echocardiographic measurements were carried out ac-
and ejection fraction 35% and without inter-current cording to the recommendations of the American Soci-
illnesses, were eligible for the study. The prevalence of ety of Echocardiography always within three hours after
diabetes mellitus in this cohort was 14% (that is, 28 blood sampling. Left ventricular mass (LVM) was calcu-
patients out of 199). Seventy-six patients had ECG-docu- lated according to the Devereux formula and indexed
mented episodes of angina or myocardial infarction ear- to height2.7 (LVMI) [21]. LVH was defined by a LVMI
lier, and 27 had transient ischemic attacks or stroke. of over 47 g/m2.7 in women or over 50 g/m2.7 in men. The
All patients were virtually anuric (24-hour urine volume height-based indexing of LV mass was specifically chosen
200 mL/day) and were being treated thrice weekly with to minimize any potential distortion attributable to ex-
standard bicarbonate dialysis (Na 138 mmol/L, HCO3 35 tracellular volume expansion (surface area indexing be-
mmol/L, K 1.5 mmol/L, Ca 1.25 mmol/L, Mg 0.75 mmol/L) ing weight-sensitive) [22]. Systolic dysfunction was de-
and cuprophan or semi-synthetic membranes (dialysis fined as a LV ejection fraction 45%.
filters surface area: 1.1 to 1.7 m2). Dry weight was estab-
Blood pressure measurementslished for each patient on a trial-and-error basis, and was
defined as the weight below which the patient suffered In hemodialysis patients, pre-dialysis blood pressures
frequent hypotensive episodes during the latter part of (BPs) were calculated as the average value of all re-
the dialysis session and experienced malaise, cramps and cordings (12 measurements, that is, 3/week) taken during
dizziness post-dialysis. Seventy-six patients were habit- the month preceding the study [23].
ual smokers (22  16 cigarettes/day). One hundred and
Statistical analysisten patients were on treatment with erythropoietin. Sev-
enty-six patients were being treated with antihyperten- Data are expressed as mean  SD or as median and
inter-quartile range. Differences between groups weresive drugs: 52 on mono-therapy with angiotensin con-
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tested by t test, Mann-Whitney test or by Chi-squared 3) adjusting for potential confounders including cardiac
ischemia (Methods section and Table 1) patients withtest, as appropriate. Variables showing a positively skewed
distribution were log transformed (lg10). Relationships serum cTnT 55 ng/L had a risk of LVH that was 3.47
(95% CI 1.54 to 7.80) times higher than in those belowbetween continuous variables were analyzed by the least
square method. this threshold (P  0.003). Systolic pressure ranked as
the strongest predictor of LVH (Table 3).The (categorical) relationships between serum cTnT,
LVH and LV systolic dysfunction were tested by multi- Serum cTnT was significantly higher (P  0.005) in
patients with LV systolic dysfunction than in those withple logistic regression analysis, adjusting for potential
confounders. Confounding variables were identified by normal LV function (Table 2), and in a fully adjusted
multiple logistic regression model (Table 3) it was thecomparing patients with and without these alterations
(Tables 1 and 2). Odds ratios and their 95% confidence second independent correlate of this alteration after
male sex. In this model, patients with serum cTnT 150intervals (CI) were calculated using the estimated regres-
sion coefficients and their standard errors in multiple ng/L had a risk of LV systolic dysfunction 3.30 (95% CI
1.16 to 9.43) times higher than in patients with serumlogistic regression analysis. The statistical models were
of adequate statistical power (at least 25 subjects for cTnT 150 ng/L (P  0.03).
each variable in the model).
Diagnostic value of cardiac troponin TThe usefulness of cTnT for the diagnosis of LVH and
LV systolic dysfunction was tested by the analysis of ROC analysis. Serum cTnT had a fair diagnostic value
for the identification of LVH and of LV systolic dysfunc-receiver operating characteristic (ROC) curves [24]. The
value of cTnT giving the best combination of sensitivity tion because the area under the corresponding ROC
curves (0.72 and 0.68, respectively) was significantlyand specificity (that is, the best “cut-off”) was calculated
as the value that maximizes the sum of the sensitivity and greater (P  0.005) than the threshold of diagnostic
indifference (50%). The best cTnT cut-off that discrimi-specificity [24]. Pre-test and post-test odds, sensitivity,
nated patients with and without LVH was 55 ng/L, whichspecificity, likelihood ratios (positive and negative) as
was lower than the best cut-off (150 ng/L) for the identi-well as posterior probabilities and positive and negative
fication of patients with LV systolic dysfunction.prediction values were calculated by standard formulas
Sensitivity, specificity, positive and negative prediction(also reported in the Appendix). All calculations were
value. Serum cTnT had a similar degree of sensitivitydone using a standard statistical package (SPSS for Win-
and specificity for the detection of LVH (70 and 69%,dows Version 9.0.1; SPSS, Inc., Chicago, IL, USA).
respectively; Table 4). The posterior probability of a
positive cTnT test was high (87%), but due to the high
RESULTS prevalence of LVH the posterior probability of a nega-
Median serum cTnT in dialysis patients was 71 ng/L tive cTnT test and the negative prediction value were
(inter-quartile range 41 to 136 ng/L). Serum cTnT con- relatively low (56 and 44%). Serum cTnT had a low
centration was below the limit of detection (cut-off at diagnostic sensitivity for the identification of LV systolic
10 ng/L) only in 12 out of 199 patients. One hundred dysfunction (52%) coupled to a high specificity (81%;
and forty-nine patients (75%) displayed LVH on echo- Table 4). In other words, cTnT appeared to be more
cardiography and 21 patients (11%) had systolic dysfunc- useful for excluding LV systolic dysfunction than for cor-
tion. All patients with systolic dysfunction also had LVH. rectly identifying this alteration. Accordingly, the posi-
Patients with LVH were older, more likely to have diabe- tive predictive value (posterior probability of a positive
tes and hypertension, to have suffered from cardiac isch- cTnT test) was rather low (25%) while the negative pre-
emia and to exhibit lower serum albumin and hemoglo- dictive value was high (93%), indicating a low posterior
bin than those with normal LV mass (Table 1). On the probability (7%).
other hand, when patients were re-classified in relation- Among the variables that had an independent rela-
ship to the presence of LV systolic dysfunction (Table tionship with LVH on multiple logistic analysis, only
2), those with systolic dysfunction were characterized by systolic pressure was independent of cTnT (Table 3).
a higher proportion of males and diabetics and by a Systolic pressure had a diagnostic potential for the identi-
greater number of patients on anti-hypertensive therapy fication of LVH similar to that of troponin (Table 3).
and with a history of cardiac ischemia. Since systolic pressure was independent of CTnT, these
two variables could be combined to identify LVH better
Serum troponin, LVH and LV systolic dysfunction: (Appendix). The combined posterior probability of high
Multivariate logistic regression analysis cTnT and systolic pressure for LVH was as high as 95%,
Serum cTnT concentration was significantly higher in while the corresponding negative posterior probability
patients with LVH than in those with normal LV mass and predictive value remained unsatisfactory (Table 4).
Male sex resulted as the only variable that was inde-(Table 1). In a multiple logistic regression model (Table
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Table 1. Somatometric, biochemical, hemodynamic and echocardiographic data of patients classified in relationship to the presence of
left ventricular hypertrophy (LVH)
Left ventricular hypertrophy
With Without
Somatometric data (N  149) (N  50)
Age years 61.013.6 52.116.9c
Male sex 81 (54.4%) 30 (60.0%)
Diabetics N % 26 (17.4%) 2 (4.0%)a
Smokers N % 61 (40.9%) 15 (30.0%)
Patients with cardiac ischemia N % 66 (44.3%) 10 (20.0%)b
Patients on anti-hypertensive treatment N % 68 (45.6%) 8 (16.0%)c
Biochemical data
Hemoglobin g/L 10518 11120a
Serum albumin g/L 415 445c
Serum cholesterol mmol/L 5.391.49 5.341.45
Serum phosphate mmol/L 2.000.46 2.000.48
Serum calcium mmol/L 2.270.25 2.270.25
Serum CRP mg/L 8.2 (3.4–18.2) 5.4 (3.4–12.0)
Plasma homocysteine lmol/L 27.0 (20.5–42.8) 22.9 (16.4–38.9)
Serum troponin ng/L 81.0 (48.5–160.5) 40.0 (21.0–91.8)b
Kt/V 1.230.28 1.190.25
Hemodynamic data
Systolic pressure mm Hg 144.924.8 128.520.9c
Diastolic pressure mm Hg 76.613.3 76.012.9
Heart rate beats/min 78.810.5 77.610.4
Echocardiographic data
Left ventricular end diastolic diameter cm 5.10.7 4.80.5c
Inter-ventricular septum cm 1.240.18 1.000.15c
Posterior wall thickness cm 1.160.18 0.930.13c
Left ventricular mass index g/m2.7 68.714.9 39.36.7c
Ejection fraction % 59.0 (52.0–65.0) 65.0 (61.0–68.0)c
Data are expressed as mean  SD, median (inter-quartile range) or as percent frequency, as appropriate; males 50 g/m2.7, females 47 g/m2.7 (see Methods).
a P  0.05, b P  0.01, c P  0.001
pendent of cTnT in the multiple logistic model of LV time consuming it is rarely applied in dialysis patients.
ECG, which is a cost-saving, easily available method,systolic dysfunction (Table 3). The combined diagnostic
estimate (cTnT and male sex) of LV systolic dysfunction has a low sensitivity for the detection of LVH and no
diagnostic utility for the screening of LV dysfunction.attained a high post-test negative prediction power (98%;
The issue is important in that left ventricular hypertro-Table 4).
phy and left ventricular dysfunction are modifiable risk
factors in these patients. Thus, simple, bedside methods
DISCUSSION are needed to if we are to tackle these cardiac complica-
In this study the measurement of serum cardiac tropo- tions on a wide scale in the dialysis population.
nin T concentration in ESRD patients on chronic hemo- Brain natriuretic peptide was the first cardiac peptide
dialysis was a fairly informative diagnostic tool for the that underwent extensive testing in the screening for
correct identification of LVH and for the exclusion of LVH and LV systolic dysfunction; it was shown that this
LV dysfunction. peptide has the potential to diagnose these alterations
It is now well established that LVH and LV dysfunc- in dialysis patients [3]. In the same vein, we reported
tion entails an ominous prognosis in the dialysis popula- that cTnT is strongly related to LV mass in clinically
tion [1, 19]. LVH in particular constitutes an exceedingly stable hemodialysis patients (abstract; Mallamaci F et al,
frequent complication and represents the strongest pre- Nephrol Dial Transplant 16:A148, 2001). Of note, cTnT
dictor of adverse cardiovascular events in these patients. is a powerful predictor of cardiovascular mortality in
LV systolic dysfunction has a prevalence rate lower than these patients [4–7] and this phenomenon is independent
that of LVH (about 15% [19]), but it is at least equally of previous cardiovascular complications [7] and cardiac
vexing in terms of morbidity and mortality. It has been ischemia (abstract; Mallamaci et al, ibid), further under-
recommended that these alterations receive special at- scoring the potential informative value of the measure-
tention in clinical practice and be properly investigated ment of this substance in clinical practice. Troponins are
in intervention studies [25]. Echocardiography is a widely in part free in the cytosol and may leak out if membrane
accepted standard for the study of alterations in LV mass damage occurs [26]. Microvascular heart disease is com-
monly associated with LVH in experimental renal failureand function. However, since this technique is costly and
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Table 2. Somatometric, biochemical, hemodynamic and echocardiographic data of patients classified in relationship to the presence of
systolic dysfunction (LV ejection fraction 45%)
Systolic dysfunction
With Without
Somatometric data (N  21) (N  178)
Age years 61.810.9 58.415.4
Male sex 18 (85.7%) 91 (51.1%)b
Diabetics N % 7 (33.3%) 21 (11.8%)b
Smokers N % 11 (52.3%) 65 (36.5%)
Patients with cardiac ischemia N % 13 (61.9%) 63 (35.4%)a
Patients on antihypertensive treatment N % 14 (66.7%) 62 (34.8%)b
Biochemical data
Hemoglobin g/L 10914 10619
Serum albumin g/L 414 425
Serum cholesterol mmol/L 5.201.55 5.351.45
Serum phosphate mmol/L 2.150.52 1.980.45
Serum calcium mmol/L 2.280.25 2.270.25
Serum CRP mg/L 11.7 (4.4–22.6) 7.3 (3.4–16.3)
Plasma homocysteine lmol/L 24.3 (17.4–40.8) 27.0 (19.6–42.3)
Serum troponin ng/L 154.0 (63.5–224.0) 70.0 (36.5–121.0)b
Kt/V 1.220.32 1.220.26
Hemodynamic data
Systolic pressure mm Hg 142.026.1 141.124.5
Diastolic pressure mm Hg 78.813.1 76.413.1
Heart rate beats/min 82.413.8 78.09.9
Echocardiographic data
Left ventricular end diastolic diameter cm 5.90.6 4.90.6c
Inter-ventricular septum cm 1.210.16 1.170.21
Posterior wall thickness cm 1.180.16 1.100.20a
Left ventricular mass index g/m2.7 82.710.6 59.017.5c
Ejection fraction % 39.0 (35.0–42.0) 62.0 (57.0–67.0)c
Data are expressed as meanSD, median (inter-quartile range) or as percent frequency, as appropriate.
aP  0.05, bP  0.01, cP  0.001
Table 3. Multiple logistic regression analysis of LVH and LV dysfunction
Independent variables Odds ratio (95% CI) P
Left ventricular hypertrophy
Systolic pressure 140 mm Hg 3.86 (1.61–9.27) 0.003
Troponin 55 ng/L 3.47 (1.54–7.80) 0.003
Antihypertensive therapy 0  no; 1  yes 3.64 (1.38–9.59) 0.009
Age 60 years 2.66 (1.16–6.06) 0.02
Albumin 35 g/L 6.31 (1.25–31.92) 0.03
Diabetes 0  no; 1  yes 2.61 (0.50–13.65) 0.26
Cardiac ischemia 0  no; 1  yes 1.33 (0.53–3.34) 0.54
Hemoglobin 110 g/L 0.94 (0.43–2.07) 0.88
Left ventricular systolic dysfunction
Male sex 7.92 (1.92–32.62) 0.004
Troponin 150 ng/L 3.30 (1.16–9.43) 0.03
Antihypertensive therapy 0  no; 1  yes 3.27 (1.13–9.45) 0.03
Diabetes 0  no; 1  yes 3.56 (1.02–12.37) 0.05
Cardiac ischemia 0  no; 1  yes 2.39 (0.82–6.95) 0.11
Data are expressed as odds ratio and 95% confidence interval (CI). The cTnT threshold values for LVH (55 ng/L) and for LV dysfunction (150 ng/L) represent
the best cut-offs for LVH and LV systolic dysfunction respectively (Methods).
[27] as well as in patients with advanced chronic renal versely related to systolic function (ejection fraction).
Troponin T anchors the troponin complex to tropomyo-failure [28]. In patients with LVH chronic ischemia deter-
mined by altered coronary microcirculation may induce sin during cardiac contraction, and for this reason it is
possible that the inverse relationship between systolicand/or amplify the leakage of cardiac troponins across
the plasma membrane of myocardial cells. Therefore, function and cTnT we observed represents another facet
of uremic microvascular heart disease. It is worth notinghigh serum cTnT in dialysis patients may be due to a
leakage of this protein from hypertrophic cardiomyo- that cross reactivity between cardiac and muscular tropo-
nin was an important analytical problem in the “firstcytes. Our current data indicate that cTnT also is in-
Mallamaci et al: Troponin T, LVH and LV systolic dysfunction 1889
generation” cTnT assay [28]. This limitation does not
apply to our study because we employed a “third genera-
tion” cTnT assay standardized with human recombinant
cTnT, which couples the lack of cross reactivity with
muscular cTnT, resulting in a substantially greater sensi-
tivity (Methods).
We found that cTnt has a fairly good diagnostic value
for the identification of LVH coupled to high diagnostic
value for the exclusion of LV systolic dysfunction. Inter-
estingly, the usefulness of cTnT for the prediction of
LVH was potentiated by combining this measurement
to that of systolic pressure, while sex augmented the
negative prediction for LV systolic dysfunction.
This study has two limitations that deserve attention.
We focused on patients without heart failure because
in this condition echocardiography is rarely omitted to
confirm the diagnosis and to plan the treatment. Al-
though likely [17, 18], the diagnostic value of cTnT in
dialysis patients with heart failure cannot be extrapo-
lated from this study. The second limitation is due to the
fact that we analyzed data on the basis of retrospectively
defined “best cut-off” values. For this reason the diagnos-
tic thresholds for LVH and LV systolic dysfunction
adopted in this study, which are specific for patients on
dialysis, remain to be prospectively tested in other dial-
ysis centers to prove the external validity of our findings.
Finally, in making the combined diagnostic estimate of
LVH, we used the average monthly (routine) pre-dialysis
pressure. This measurement can be easily obtained from
clinical files and it is systematically calculated in many
dialysis units. This BP estimate is related to LV mass as
strongly as 24-hour ambulatory monitoring [24]. For this
reason, casual systolic pressure cannot be considered a
valid surrogate of the average monthly estimate.
Besides predicting mortality, cTnT has a fairly good
diagnostic potential for the identification of LVH and
the exclusion of LV systolic dysfunction in patients with
ESRD without heart failure. Third generation cTnT
assays are rapid, reliable and highly specific for cardiac
troponin. Our data suggest that this marker may be use-
ful to screen for alterations in LV mass and function in
clinically stable dialysis patients.
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